Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05120830 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Study acronym: NTLA-2002
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Jul 2026 to May 31, 2027
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Publications: details revised at 2 of 2 entries
  2. Study completion date: Mar 31, 2026 to Jul 2026v12
  3. Study arms: 3 to 4v11
  4. Study sites: 8 to 9v10
  5. Study sites: 9 to 8
    • Primary completion date changed from estimate of Apr 15, 2024 to Apr 4, 2024
    • Study completion date: Dec 15, 2025 to Mar 31, 2026
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 55 to confirmed 37
    • Site details revised at 9 of 9 sites
    v8
  2. Study sites: 7 to 9v7
  3. Study sites: 4 to 7v6
  4. Study sites: 3 to 4v5
  5. Site details revised at 1 of 3 sitesv4
  6. Primary endpoints revised (2)
    • Study sites: 1 to 3
    • Start date changed from estimate of Nov 15, 2021 to Dec 10, 2021
    • Secondary endpoints: 6 to 5
    v3
  7. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).
Trial Details
NCT Number NCT05120830
Lead Sponsor Intellia Therapeutics
Conditions
(from sponsor)		 Hereditary Angioedema
Related terms Angioedemas, Hereditary
Enrollment 37 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov